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Abstract
Objective: To evaluate impact of germline BRCA mutational status on prognosis in patients with advanced ovarian cancer.
Methods: A total of 128 patients diagnosed with FIGO stage III-IV high-grade serous ovarian cancer (HGSOC) between
2008 and 2017 and underwent BRCA1/2 gene testing at the time of or within two years from cancer diagnosis were
included in this study. We compared patients’ clinicopathological characteristics and survival outcomes after primary
treatment according to germline BRCA mutational status. Treatment-related factors that might affect patients’ survival
outcome were also investigated.
Results: Germline BRCA1/2mutations were observed in 51 women (39.8%). There were no differences in age and serum
CA-125 levels at the time of HGSOC diagnosis, use of neoadjuvant chemotherapy (NAC), extent of debulking surgery, and
overall survival (OS) between the BRCA mutation and wild-type BRCA groups. In contrast, the BRCA mutation group
displayed longer progression-free survival (PFS) (median, 22.9 vs. 16.9months, P= 0.001). Multivariate analyses identified
germline BRCA1/2 mutation as an independent favorable prognostic factor for PFS (adjusted HR, 0.502; 95% CI, 0.318–0.795;
P= 0.003). In the wild-type BRCA group, patients who received NAC as the primary treatment had shorter PFS compared to
those who received primary debulking surgery (PDS) (median, 14.2 vs. 16.9months, P= 0.003). However, in the BRCA
mutation group, PFS did not differ between the NAC and PDS groups (P= 0.082).
Conclusions: In advanced-stage HGSOC, patients with germline BRCA1/2mutations have better prognosis with longer PFS
than those lacking BRCA mutations. Prognosis after NAC was different according to the BRCA mutational status.
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Introduction
Ovarian cancer is the deadliest gynecologic malignancy,
accounting for 226,000 new cases and 158,000 cancer
deaths globally each year [1]. In Korea, ovarian cancer
has been gradually increasing [2]. Germline mutations in
BRCA1 or BRCA2 gene confer a high risk of developing
ovarian cancer [3, 4]. A recent prospective cohort study
estimated the cumulative ovarian cancer risk to age 80
years as 44% (95% confidence interval [CI], 36–53%) for
BRCA1 and 17% (95% CI, 11–25%) for BRCA2 mutation
carriers [4].
The majority (90%) of ovarian cancers are epithelial
ovarian cancers (EOCs) [5]. High-grade serous ovarian
cancer (HGSOC), the most prevalent and lethal form
among EOCs, is of particular interest because approxi-
mately 20% of patients with this histology have germline
BRCA1/2 mutations [6]. Three recent randomized trials
on maintenance therapy with poly(adenosine diphospha-
te)-ribose polymerase (PARP) inhibitors showed signifi-
cantly improved progression-free survival (PFS) in
BRCA mutated, platinum-sensitive relapsed HGSOC:
olaparib in the SOLO-2 trial [7], rucaparib in the
ARIEL3 trial [8], and niraparib in the NOVA trial [9].
The ability to identify patients with germline BRCA1/2
mutations and evaluate their clinical outcomes are im-
portant issues in HGSOC.
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To date, the exact effect of germline BRCA1/2 muta-
tions on ovarian cancer prognosis has not yet been de-
termined. Several studies reported that patients with
germline BRCA mutations have better prognosis, prob-
ably due to the high response rate to platinum-based
chemotherapy [10–15]; although, other studies reported
heterogeneous results [16–18]. Favorable prognosis was
associated only with BRCA2 mutated EOC, but not with
BRCA1 mutated patients [17, 18]. The study population
heterogeneity and ethnicity hinder the evaluation of
exact relationship between the survival outcomes and
germline BRCA1/2 mutations. Furthermore, BRCA1 is a
relatively large gene and its protein product has three
representative domains, frequently mutated in cancer
patients with relatively high frequency [19]. Mutations in
the different domains might result in differences in can-
cer prognosis.
More precise knowledge regarding the effects of BRCA
gene mutations on HGSOC prognosis and treatment
method success would allow for the development of indi-
vidualized treatment plans for patients with HGSOC. In
addition, it is necessary to present scientific evidences on
these issues in patients of Korean ethnicity. Thus, this
study aimed to evaluate the effect of BRCA mutational
status on clinical outcome in patients with advanced-stage
HGSOC. We also investigated treatment-related factors
that might affect HGSOC patients’ survival outcome, in-
cluding use of neoadjuvant chemotherapy (NAC) and ex-
tent of debulking surgery.
Materials and methods
This retrospective case-control study was conducted
after obtaining approval from the Institutional Review
Board of Seoul National University Hospital (IRB No.
1712–083-907).
Study population
At our institutional hospital, we recommend germline
BRCA1/2 gene testing to all women with pathologically
proven EOC in accordance with the position statements
of the Korean Society of Gynecologic Oncology [20].
Previously, germline BRCA1/2 gene testing was per-
formed using direct sequencing (Sanger sequencing), in-
cluding whole exon and exon-intron boundaries of
BRCA1 and BRCA2. However, since February 2016,
next-generation sequencing (NGS) of BRCA1 and
BRCA2 genes have been available and actively used.
Germline mutations, discovered by NGS, were validated
by Sanger sequencing. To determine whether the detected
mutations were previously identified, we searched the
Breast Cancer Information Core (BIC) database (https://
research.nhgri.nih.gov/projects/bic/), the National Insti-
tutes of Health open-access database of clinically observed
variants and their classification (ClinVar) (https://www.
ncbi.nlm.nih.gov/clinvar/), and the previously published
Korean germline BRCA1/2 mutations [21–25]. In this
study, patients with BRCA1 or BRCA2 gene sequence var-
iants which were previously reported as deleterious muta-
tions or classified as likely pathogenic or pathogenic
according to the American College of Medical Genetics
and Genomics and the Association for Molecular Path-
ology guidelines [26] were assigned to the BRCA mutation
group. Otherwise, they were assigned to the wild-type
BRCA group.
From our institution’s Ovarian Cancer Cohort Data-
base, we searched relevant patients to identify those who
met the following inclusion criteria: (1) diagnosed with
EOC and treated between July 2008 and December
2017; (2) International Federation of Gynecology and
Obstetrics (FIGO) stage III-IV disease; (3) High-grade
serous histologic type; and (4) received germline
BRCA1/2 gene testing at the time of or within 2 years
from cancer diagnosis. Patients with insufficient clinical
and/or pathologic data were excluded from the study.
Figure 1 depicts the selection of the study population.
Of the 128 patients with advanced-stage HGSOC who
met these criteria, 51 (39.8%) and 77 (60.2%) were in-
cluded in BRCA mutation group and wild-type BRCA
group, respectively. Thereafter, we compared clinico-
pathological characteristics and clinical outcomes be-
tween the two groups.
Three representative domains of the BRCA1 protein
are as follows: 1) the N-terminal Really Interesting New
Gene (RING) domain (exons 2–7); 2) Exons 11–13, that
covers over 65% of the sequence of BRCA1; and 3) the
BRCA1 C-terminal (BRCT) domain (exons 16–24) [19].
Considering these three domains, 37 patients of the
BRCA mutation group were divided into three sub-
groups depending on the position of BRCA1 mutations,
and their survival outcomes were compared.
Data collection
We reviewed medical records to collect information
about clinicopathological characteristics, such as age and
serum CA-125 levels at diagnosis, and FIGO stage, and
primary treatment of EOC, such as use of NAC and ex-
tent of residual tumour after debulking surgery. Optimal
debulking was defined when the maximal diameter of re-
sidual tumour was less than 1 cm. Whether the patients
received NAC followed by interval debulking surgery or
primary debulking surgery (PDS), all patients received
post-operative adjuvant taxane- and platinum-based
chemotherapy as the primary treatment. However, none
of them received any PARP inhibitors. Patients’ personal
and familial histories at the time of HGSOC diagnosis
were retrieved from medical records. We collected the
patients’ parity, menstruation status, personal and famil-
ial history of breast cancer and ovarian cancer, and the
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number of relatives (up to second-degree family mem-
bers) who had a history of breast or ovarian cancers.
PFS was calculated as the time interval between the
date of initial diagnosis and the date of disease progres-
sion using the Response Evaluation Criteria in Solid Tu-
mours version 1.1 [27]. Treatment-free interval (TFI)
was calculated as the time interval between the date of
completion of primary treatment and the date of disease
progression. Platinum-sensitive recurrence (PSR) was
defined when the TFI was 6 months or longer, whereas
platinum-resistant recurrence (PRR) was defined when
the TFI was shorter than 6 months. Overall survival
(OS) was calculated as the time interval between the
date of initial diagnosis to the date of cancer-related
death or end of the study.
Statistical analysis
Differences in clinicopathological characteristics were
evaluated between the two groups: Student’s t-test and
Mann-Whitney U-test were used to compare continuous
variables, and Pearson’s chi-squared test and Fisher’s
exact test were used to compare categorical variables.
The Kaplan-Meier methods with log-rank test were used
for survival analyses. Hazard ratios (HRs) and 95% CIs
were calculated using Cox proportional hazards regres-
sion models. We used SPSS software (version 21.0; SPSS
Inc., Chicago, IL, USA) for these analyses. All statistical
tests were two-sided, and a P value < 0.05 was consid-
ered statistically significant.
Results
Characteristics of study population
The patients’ clinicopathological characteristics are pre-
sented in Table 1. No differences in age and serum
CA-125 levels at the time of HGSOC diagnosis, use of
NAC, and rates of optimal debulking surgery were ob-
served between the BRCA mutation group and the
wild-type BRCA group. The time interval between diag-
nosis and genetic test was not different either. Distribu-
tions of FIGO stage IIIA1 to IVB were not different
between the two groups (P = 0.077). However, FIGO
stage IV disease were less common in the patients who
have BRCA mutation compared to those with BRCA
wild-type (25.5% vs. 49.4%, P = 0.007). In the BRCA mu-
tation group, 37 (72.5%) and 14 (27.5%) patients had
mutation in BRCA1 or BRCA2, respectively; no patients
had double mutations.
Fig. 1 Flow diagrams depicting the selection of the study population
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The patients’ personal and familial histories are pre-
sented in Additional file 1: Table S1. There were no
differences in parity, menstruation status, and familial
history of ovarian cancer between the two groups.
However, patients with BRCA mutations had signifi-
cantly higher personal history of breast cancer (23.5%
vs. 7.8%, P = 0.012) and familial history of breast can-
cer (27.5% vs. 2.6%, P < 0.001) than those in the
wild-type BRCA group. The number of relatives with
breast cancer was also higher in the BRCA mutation
group (P < 0.001).
Additional file 1: Table S2 depicts clinicopathological
characteristics of patients according to the primary treat-
ment strategy. In the BRCA mutation group, age and
serum CA-125 levels at diagnosis, and residual tumour
after surgery were similar between patients who received
PDS and those with NAC. However, FIGO stage IV dis-
ease were more frequent in patients with NAC (47.4%
Table 1 Clinicopathological characteristics of patients at diagnosis of epithelial ovarian cancer
Characteristics All (n=128, %) BRCA mutation (n=51, %) BRCA wild-type (n=77, %) P
Age, years
Mean ± SD 56.4 ± 10.3 54.7 ± 9.9 57.5 ± 10.4 0.130
<50 39 (30.5) 20 (39.2) 19 (24.7) 0.080
≥50 89 (69.5) 31 (60.8) 58 (75.3)
BMI, kg/m2
Mean ± SD 23.4 ± 3.5 23.2 ± 3.7 23.6 ± 3.5 0.576
CA-125, IU/ml
Median (range) 921.5 (13.0−10000.0) 795.0 (34.9−9926.0) 1296.0 (13.0−10000.0) 0.724
FIGO stage 0.077
III 77 (60.2) 38 (74.5) 39 (50.6) 0.007
IIIA1 4 (3.1) 3 (5.9) 1 (1.3)
IIIA2 4 (3.1) 1 (2.0) 3 (3.9)
IIIB 12 (9.4) 5 (9.8) 7 (9.1)
IIIC 57 (44.5) 29 (56.9) 28 (36.4)
IV 51 (39.8) 13 (25.5) 38 (49.4) 0.007
IVA 6 (4.7) 1 (2.0) 5 (6.5)
IVB 45 (35.2) 12 (23.5) 33 (42.9)
Primary treatment strategy 0.846
PDS 79 (61.7) 32 (62.7) 47 (61.0)
NAC 49 (38.3) 19 (37.3) 30 (39.0)
Residual tumor after PDS/IDS 0.192
Optimal debulking 109 (85.2) 46 (90.2) 63 (81.8)
Suboptimal debulking 19 (14.8) 5 (9.8) 14 (18.2)
Recurrence
No 39 (30.5) 20 (39.2) 19 (24.7) 0.080
Yes 89 (69.5) 31 (60.8) 58 (75.3)
Platinum-sensitive recurrence 62 (48.4) 25 (49.0) 37 (48.1) 0.099
Platinum-resistant recurrence 27 (21.1) 6 (11.8) 21 (27.3)
BRCA mutation
BRCA1 37 (28.9) 37 (72.5)
BRCA2 14 (10.9) 14 (27.5)
Both 0 (0) 0 (0)
Interval between diagnosis and genetic test, months
Median (range) 3.5 (0−22.7) 2.6 (0−22.4) 4.3 (0.1−22.7) 0.065
Abbreviations: BMI body mass index, CA-125 cancer antigen 125, FIGO International Federation of Gynecology and Obstetrics, PDS primary debulking surgery, NAC
neoadjuvant chemotherapy, IDS interval debulking surgery, SD standard deviation
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vs. 12.5%, P = 0.009). In the wild-type BRCA group, pa-
tients with NAC had higher initial serum CA-125 levels
(median, 1946.0 vs. 764.0, P = 0.011) and showed a trend
towards more FIGO stage IV disease (63.3% vs. 40.4%, P =
0.050), compared to those with PDS. However, proportions
of patients who achieved optimal debulking surgery were
not different; 86.7 and 78.7% of patients who received NAC
and PDS, respectively (P = 0.378).
Comparisons of survival outcome between the BRCA
mutation and wild-type BRCA groups
The median observation period was 26.3 months (range,
8.1–94.4 months). During this time, 31 patients (60.8%)
in the BRCA mutation group and 58 patients (75.3%) in
the wild-type BRCA group experienced disease recur-
rence. Among them, the median TFI was longer in the
patients with BRCA mutations (12.3 months vs. 9.0
months, P = 0.002). However, the proportions of those
with PSRs among the recurred were similar between the
two groups (80.6% vs. 63.8%, P = 0.099).
Survival outcomes for the BRCA mutation and wild-
type BRCA groups are presented in Fig. 2. There were
no significant differences in OS between the two groups
(5-year survival rates, 75.1% vs. 66.4%, P = 0.257). By
contrast, patients in the BRCA mutation group had sig-
nificantly longer PFS than those in the wild-type BRCA
group (median, 21.7 vs. 15.4 months, P = 0.001). In terms
of specific BRCA gene type, the patients who had
BRCA1 mutation and those who had BRCA2 mutation
showed no differences in PFS (median, 21.7 vs. 26.7
months, P = 0.612).
Multivariate analyses adjusting age, FIGO stage, pri-
mary treatment strategy, residual tumour after debulking
surgery, and BRCA mutational status revealed only NAC
(compared to PDS) as an independent poor prognostic
factor for OS (adjusted HR, 4.098; 95% CI, 1.478–
11.359; P = 0.007) (Table 2). Meanwhile, the BRCA1/2
mutation was identified as an independent favorable
prognostic factor for PFS (adjusted HR, 0.502; 95% CI,
0.318–0.795; P = 0.003), and NAC was also associated
with poor PFS (adjusted HR, 2.103; 95% CI, 1.321–3.348;
P = 0.002) (Table 3).
Comparisons of survival outcome according to the
primary treatment strategy
Next, we compared the survival outcomes in all patients ac-
cording to the primary treatment strategy (Additional file 1:
Figure S1). Patients who received NAC had significantly
poorer survival outcomes than those who received PDS
(OS, P = 0.003; and PFS, P < 0.001). We performed sub-
group analyses considering BRCA mutational status. In the
wild-type BRCA group, compared to PDS, patients who re-
ceived NAC had poorer PFS (median, 14.2 vs. 16.9months,
P = 0.003), whereas no differences in OS were observed
(Fig. 3 a, b). In the BRCA mutation group, patients who re-
ceived NAC showed poorer OS (5-year survival rates,
57.9% vs. 82.8%; P = 0.040). However, PFS was not different
between NAC and PDS treatments (median, 17.2 vs. 26.7
months; P = 0.082) (Fig. 3 c, d).
Lastly, we also performed subgroup analyses limited to
the specific primary treatment strategy. In PDS group,
multivariate analyses revealed that BRCA mutational sta-
tus did not affect both OS and PFS (Additional file 1:
Table S3). However, in NAC group, the BRCA1/2 muta-
tion was identified as an independent favorable prognos-
tic factor for PFS (adjusted HR, 0.433; 95% CI, 0.202–
0.926; P = 0.031). Suboptimal deublking was a poor prog-
nostic factor for PFS (adjusted HR, 3.753; 95% CI,
1.294–10.890; P = 0.015) (Additional file 1: Table S4).
Comparisons of survival outcome according to the
position of BRCA1 gene mutation
Detailed deleterious BRCA1 gene mutations of 37 pa-
tients in the BRCA mutation group are displayed in
Fig. 2 Survival outcomes of BRCA mutation and wild-type BRCA groups. a Overall survival. b Progression-free survival. c Progression-free survival
according to the mutated BRCA gene
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Additional file 1: Table S5. The most frequently mutated
domain was exons 11–13, in which 24 (64.9%) patients
were included. Of the others, 6 (16.2%) and 7 (18.9%) pa-
tients had mutations in the N-terminal RING domain and
BRCT domain, respectively. All 6 mutations in the
N-terminal RING domain were the same nonsense muta-
tion. In survival analysis, the three subgroups showed
similar OS (P = 0.643) and PFS (P = 0.963) (Additional file
1: Figure S2).
Discussion
This study analysed correlations between BRCA muta-
tional status and clinical outcome in patients with
advanced-stage HGSOC. Patients with germline BRCA1/2
Table 2 Factors associated with overall survival
Characteristics N Univariate analysis Multivariate analysis
HR 95% CI P Adjusted HR 95% CI P
Age, years
<50 39 1 (Ref) − − 1 (Ref) − −
≥50 89 2.848 0.825−9.835 0.098 2.407 0.668−8.670 0.179
FIGO stage
III 77 1 (Ref) − − 1 (Ref) − −
IV 51 2.055 0.734−5.753 0.170 1.248 0.434−3.591 0.682
Primary treatment strategy
PDS 79 1 (Ref) − − 1 (Ref) − −
NAC 49 3.790 1.483−9.691 0.005 4.098 1.478−11.359 0.007
Residual tumor after PDS/IDS
Optimal debulking 109 1 (Ref) − − 1 (Ref) − −
Suboptimal debulking 19 1.723 0.545−5.442 0.354 1.935 0.559−6.703 0.298
BRCA status
Wild-type 77 1 (Ref) − − 1 (Ref) − −
Mutation 51 0.584 0.228−1.495 0.262 0.768 0.283−2.082 0.603
Abbreviations: CA-125 cancer antigen 125, FIGO International Federation of Gynecology and Obstetrics, PDS primary debulking surgery, NAC neoadjuvant
chemotherapy, IDS interval debulking surgery, HR hazard ratio, CI confidence interval, Ref reference
Table 3 Factors associated with progression-free survival
Characteristics N Univariate analysis Multivariate analysis
HR 95% CI P Adjusted HR 95% CI P
Age, years
<50 39 1 (Ref) − − 1 (Ref) − −
≥50 89 1.540 0.958−2.477 0.075 1.377 0.850−2.232 0.194
FIGO stage
III 77 1 (Ref) − − 1 (Ref) − −
IV 51 1.903 1.244−2.912 0.003 1.358 0.867−2.126 0.182
Primary treatment strategy
PDS 79 1 (Ref) − − 1 (Ref) − −
NAC 49 2.098 1.373−3.206 0.001 2.103 1.321−3.348 0.002
Residual tumor after PDS/IDS
Optimal debulking 109 1 (Ref) − − 1 (Ref) − −
Suboptimal debulking 19 1.515 0.867−2.648 0.145 1.587 0.879−2.865 0.126
BRCA status
Wild-type 77 1 (Ref) − − 1 (Ref) − −
Mutation 51 0.484 0.310−0.755 0.001 0.502 0.318−0.795 0.003
Abbreviations: CA-125 cancer antigen 125, FIGO International Federation of Gynecology and Obstetrics, PDS primary debulking surgery, NAC neoadjuvant
chemotherapy, IDS interval debulking surgery, HR hazard ratio, CI confidence interval, Ref reference
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mutations had better prognosis with longer PFS than
those with wild-type BRCA1/2 genes. In terms of specific
BRCA gene type, BRCA1 mutation and BRCA2 mutation
showed no differences in PFS.
In Korea, the National Health Insurance System ap-
proved and started to cover BRCA1/2 gene testing for
patients with EOC. In addition, we recommend germline
BRCA1/2 gene testing to all women with pathologically
proven EOC at our institutional hospital. Nevertheless,
real-world uptake rate of the gene testing was less than
70% in our hospital: Of 280 patients diagnosed with
FIGO stage III-IV HGSOC, 181 patients received germ-
line BRCA1/2 gene testing (64.6%). A high cost and cul-
tural factors, such as social stigma and guilty feelings to
familial members, might hinder patients from germline
gene testing. It is obvious that the longer patients sur-
vive, the more they tend to get tested. Thus, we confined
the study population to those who received germline
BRCA1/2 gene testing at the time of or within 2 years
from cancer diagnosis to minimize survival bias.
Previous studies evaluated the effects of germline
BRCA1/2 mutations on EOC prognosis. Some studies
reported that only OS, not PFS, was significantly longer
in the BRCA mutation group compared to the wild-type
BRCA group [10–12]. Other studies reported that both
OS and PFS were significantly improved in the BRCA
mutation group [6, 14, 15]. An Israeli nationwide study
reported improved long-term survival in BRCA1/2 mu-
tation carriers [13]. Analyses of The Cancer Genome
Atlas project revealed that BRCA2 mutation, but not
BRCA1 mutation, was associated with significantly im-
proved OS and PFS [18]. Herein, our study provides fur-
ther evidence that BRCA mutation is associated with
improved PFS. We admit the proportion of patients with
stage IV was significantly higher in the BRCA wild-type
group, compared with the BRCA mutation group. Subopti-
mal debulking surgery was more common in the BRCA
wild-type group without statistical significance. This might
influence on better survival outcome in the BRCAmutation
group. However, we performed multivariate analyses
Fig. 3 Comparisons of survival outcomes in the wild-type BRCA group (upper) and in the BRCA mutation group (lower) according to the primary
treatment strategy. a, c Overall survival. b, d Progression-free survival
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adjusting these factors, and concluded that BRCA muta-
tional status significantly affects patients’ survival outcome.
Better survival outcome of HGSOC with germline
BRCA1/2 mutation is probably due to distinct clinical
features and a high response rate to platinum-based
chemotherapy. Both BRCA1 and BRCA2 are tumour
suppressor genes, and their functioning proteins have
major roles in DNA double-strand break repair through
homologous recombination (HR) [28–30]. In the ab-
sence of functional BRCA1/2 genes, HGSOC have un-
stable genomes that are deficient in HR repair. This
causes increased sensitivity to DNA-damaging chemo-
therapeutic agents, which is known as synthetic lethality
[31]. In the current study, none of the patients received
PARP inhibitors (e.g., olaparib), which are proven to increase
PFS in patients with BRCA-mutated, platinum-sensitive re-
lapsed ovarian cancer. Therefore, we believe that our study
results show the relatively pure effect of BRCA mutational
status on survival outcome in advanced-stage HGSOC.
In fact, the BRCA1 gene is a large gene with 24 exons
encoding a protein of 1863 amino acids. The N-terminal
RING domain is an important element of ubiquitin E3
ligases, which catalyze protein ubiquitination [32], and
the BRCT domain is essential for repair of DNA [33].
Each functional domains are known to have selected
binding partners [34]. Up to our knowledge, little is
known about the clinical effects of differently mutated
BRCA1 domains on prognosis of HGSOC. However, dif-
ferences in survival outcomes were not observed accord-
ing to the position of BRCA1 gene in this study; small
sample size might hinder the exact impact. Therefore,
further large studies are warranted.
In the current study, patients who received NAC
showed significantly poorer OS and PFS than those who
received PDS (P = 0.003 and P < 0.001, respectively). This
might originate from gynecologic oncologists’ preference
to PDS at our institution. To ellucidate whether patients
with BRCA1/2 mutations have more favorable responses to
NAC and better survival outcomes or not, we compared
survival outcomes among 49 patients who received NAC ac-
cording to the BRCA mutational status. While no difference
in OS was observed between the BRCA mutation and
wild-type BRCA groups (median, 67.2 and 47.8months, P =
0.231), patients with germline BRCA mutations had im-
proved PFS (median, 17.2 and 14.2months, P= 0.014).
Multivariate analyses revealed that the BRCA1/2 mutation
was an independent favorable prognostic factor for PFS.
These results are similar to those of a recent
multi-institutional study [35]. However, its study design was
quite different: the authors did not confine the study popu-
lation to the specific histologic type of EOC and performed
three-group comparisons; patients with germline BRCA1/2
mutations, patients without germline BRCA1/2 mutations,
and patients with no genetic testing.
Furthermore, we compared patients’ survival outcomes
according to the primary treatment strategy in the
wild-type BRCA group. Despite of no differences in
characteristics such as FIGO stage and residual tumour
after surgery, patients who received NAC had signifi-
cantly poorer PFS than those who received PDS (me-
dian, 14.2 vs. 16.9 months, P = 0.003). Similar results
were also reported in a previous retrospective multicen-
ter study of Petrillo et al. [36]. In the BRCA1/2 mutation
group, although stage IV disease were more frequent in
NAC group, PFS did not differ between the NAC and
PDS groups (P = 0.082). However, the NAC group
showed significantly poorer OS (5-year survival rates,
57.9% vs. 82.8%; P = 0.040).
The BRCA mutational status might differentially affect
survival outcomes after different primary treatment
strategies due to different initial disease patterns of
HGSOC and different responses to chemotherapy.
HGSOC patients with BRCA1/2 mutations had signifi-
cantly higher peritoneal tumour load and significantly
increased frequency of bulky lymph nodes at diagnosis
than those with wild-type BRCA genes [36]. A recent
retrospective study also reported that nodular peritoneal
disease pattern was significantly associated with BRCA
mutations, whereas mesenteric involvement and supra-
diaphragmatic lymphadenopathy were significantly asso-
ciated with wild-type BRCA genes [37]. Although we did
not evaluate initial disease patterns, these features might
have affected physician’s selection of a primary treatment
strategy. Nevertheless, the high response rate to
platinum-based chemotherapy in patients with BRCA1/2
mutations might have similarly affected both NAC and
PDS cases, leading to no observable differences in PFS.
Ovarian cancers are known to develop in younger
women with germline BRCA1/2 mutations than other-
wise. In the current study, mean age at HGSOC diagnosis
for those with BRCA mutations was approximately 3 years
younger than for those with wild-type BRCA genes, how-
ever, without statistical significance (P = 0.130). We also
observed that patients in BRCA mutation group had sig-
nificantly higher personal history and family history of
breast cancers reflecting the fact that mutations in the
BRCA1/2 genes is the most common cause of hereditary
forms of both breast and ovarian cancer.
Currently, the National Comprehensive Cancer Network
guidelines recommend that all women with epithelial ovar-
ian, fallopian tube, and primary peritoneal cancers be re-
ferred for genetic risk evaluation and be subjected to
BRCA1/2 gene testing [38]. In addition to this, we suggest
that BRCA1/2 gene testing should be performed as soon as
possible after EOC has been diagnosed. Because prediction
of cancer prognosis and implementation of individualized
treatment (e.g., assignment of the patients to PDS or NAC
as primary treatment or administration of maintenance
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PARP inhibitors) would be facilitated based on the early
genetic test results. However, in the same way as now, it is
difficult in reality. For example, the median time interval
between EOC diagnosis and genetic test was 3.5months in
this study, which was too late to determine patients’ pri-
mary treatment strategy. Time required for BRCA1/2 gene
sequencing and analysis itself should be also shortened con-
siderably. We should change the way we do it now.
This study has several limitations. First, selection bias
and other issues may be present due to the retrospective
study design. Second, the sample size and death events
might be insufficient to properly assess OS. Third, only
the primary treatment was investigated in detail. Never-
theless, in our current study, the study population was
more specific than in previous studies: only the patients
with advanced-stage HGSOC were selected. We also tried
to minimize survival bias by confining the study popula-
tion to those who received germline BRCA1/2 gene test-
ing less than 2 years from initial diagnosis. From the
clearly defined methods, our study results provide valu-
able information that can be applied in clinical practice.
Conclusions
In conclusion, we identified germline BRCA1/2 mutation
as a prognostic factor to improve survival outcomes in
advanced-stage HGSOC. We also provide evidence that
BRCA mutational status has a major influence on HGSOC
prognosis. BRCA1/2 gene testing might be a useful tool to
provide individualized treatment. For HGSOC patients
with wild-type BRCA, PDS appears to be a better choice
for primary treatment than NAC. In contrast, PFS did not
differ according to the primary treatment strategy for pa-
tients with germline BRCA1/2 mutations. These results
require validation in larger prospective cohort studies.
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